Mitoxantrone in the treatment of acute leukemia |
| |
Authors: | Daniel A Vorobiof Geoffrey Falkson Maria A Coccia-Portugal Aletta P S Terblanche |
| |
Institution: | (1) Department of Medical Oncology, University of Pretoria, Pretoria, Republic of South Africa;(2) Department of medical Oncology, University of Pretoria, Private Bag X169, 0001 Pretoria, Republic of South Africa |
| |
Abstract: | Summary Forty-six patients with acute leukemia were treated with mitoxantrone as a single agent. Twenty-nine patients had relapsed and/or refractory acute leukemia. Seventeen patients with acute non-lymphatic leukemia had received no prior treatment. Twelve mg/m2 of mitoxantrone was given intravenous on five consecutive days. Treatment related side effects included bone marrow suppression, mucositis, alopecia, nausea, vomiting and infection. Cardiotoxicity was documented in 7 patients. This study reconfirms that mitoxantrone is an active agent in acute leukemia with complete response documented in 10 of 29 patients with relapsed and/or refractory acute leukemia (34% response rate, 95% confidence limits 18–53%) and complete response documented in 11 of 17 patients (65% response rate, 95% confidence limits 38–87%) with previously untreated acute non-lymphatic leukemia. |
| |
Keywords: | acute leukemia mitoxantrone |
本文献已被 SpringerLink 等数据库收录! |
|